The objective of WP 3.4 is to jointly analyze the results from ‘omics technologies together with the results from conventional toxicology methods.
To deal with the data heterogeneity, data pre-processing such as quality assessment, scaling, and normalization are performed. After that, information regarding time and dose relationships and toxicity outcomes for each compound and technology are studied individually and across compounds. In a further step, data across the different technology platforms and from the classical clinical measurements and observations are analyzed. Extended data analysis steps will include all available information across all compounds for each technology and finally across all compounds and across all technologies.
The approaches applied will include unsupervised and supervised statistical algorithms applicable for the type of data provided by the InnoMed PredTox consortium. This data analysis also includes biological and functional information, and will lead to the generation of mechanistic hypotheses related to the cause or the progression of toxic lesions. Therefore this integrative analysis should allow the definition of sets of markers that can be proposed as safety biomarkers.
Site Navigation
Data processing and development of bio-statistical models